Search Results
Your search for s matches 6887 pages
Showing 3301 - 3350FDA Approves CAR T-Cell Therapy to Treat Adults With Certain Types of Large B-Cell Lymphoma
On October 18, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment....
Immunotherapy for Advanced Soft-Tissue and Bone Sarcoma
The phase II SARC028 trial has shown activity of pembrolizumab (Keytruda) in some subtypes of advanced sarcoma. These findings were reported by Tawbi et al in The Lancet Oncology. Study Details In the study, 84 patients with advanced soft-tissue sarcoma aged ≥ 18 years (n = 42) or bone sarcoma ...
Norman E. Sharpless, MD, Sworn in as Director of the National Cancer Institute
Norman E. “Ned” Sharpless, MD, took the oath of office late Tuesday, October 17, 2017, to become the 15th Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). He succeeds Harold E. Varmus, MD, who stepped down as Director in March 2015....
IASLC 2017: Research Confirms IASLC Characterization of Uncertain R Status With Prognosis Between R0 and R1
The findings of a recent study confirm the International Association for the Study of Lung Cancer (IASLC)’s proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification. John Edwards, PhD, MBChB, of the University of Sheffield in the United Kingdom,...
Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Risk in Type 2 Diabetes
A study in the UK population has shown that long-term use of the long-acting insulin glargine was associated with increased risk of breast cancer among women with type 2 diabetes. The findings were reported by Wu et al in the Journal of Clinical Oncology. Study Details The study involved a...
FDA Grants Priority Review for Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma
On October 16, the U.S. Food and Drug Administration (FDA) determined the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review. The FDA granted...
IASLC 2017: CheckMate-032: Nivolumab Alone or With Ipilimumab in Recurrent SCLC With High Tumor Mutation Burden
At the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer in Yokohama, Japan, Bristol-Myers Squibb announced data evaluating nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) in previously treated small cell lung cancer (SCLC) patients whose...
FDA Clears 7T Magnetic Resonance Imaging Device
On October 12, the U.S. Food and Drug Administration (FDA) cleared the first 7-Tesla (7T) magnetic resonance imaging (MRI) device, more than doubling the static magnetic field strength available for use in the United States. The Magnetom Terra is the first 7T MRI system cleared for clinical use in...
FDA Grants Priority Review for Abemaciclib as Initial Treatment of Advanced Breast Cancer
On October 12, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation to its New Drug Application (NDA) for abemaciclib (Verzenio), a cyclin-dependent kinase (CDK) 4/6 inhibitor. MONARCH 3 The NDA was based upon the positive interim...
Role of the E7 Gene in High-Risk HPV
National Cancer Institute (NCI) researchers have found that for the most common high-risk type of human papillomavirus (HPV) to cause cervical cancer, an important viral gene may need to have a precise DNA sequence. The findings, published by Mirabello et al in Cell, contribute to a better...
Osimertinib Granted Breakthrough Therapy Designation for First-Line Treatment of EGFR Mutation–Positive NSCLC
On October 9, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for osimertinib (Tagrisso) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung ...
Relationship Between Targeted HER2 Therapy and Breast Reconstruction
Trastuzumab (Herceptin) therapy for breast cancers that express the HER2 protein does not increase the risk of complications at the surgical site in women who undergo immediate breast reconstruction after mastectomy, according to findings published by Shammas et al in the Journal of the American...
Potential Biomarkers to Identify Patients at Risk for Neurotoxicity From CAR T-Cell Therapy
Although lymphodepletion chemotherapy followed by an infusion of CD19-targeted chimeric antigen receptor (CAR)-modified T cells has produced high response rates in phase I studies of patients with refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia...
Cancers Associated With Overweight and Obesity Make Up 40% of Cancers Diagnosed in the United States
Overweight and obesity are associated with increased risk of 13 types of cancer—and these cancers account for about 40% of all cancers diagnosed in the United States in 2014—according to the latest Vital Signs report by the Centers for Disease Control and Prevention (CDC). Overall, the...
Brentuximab Vedotin Granted FDA Breakthrough Therapy Designation in Front-Line Advanced Hodgkin Lymphoma
On October 2, Seattle Genetics, Inc, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to brentuximab vedotin (Adcetris) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin lymphoma. The positive ...
Immunotherapy for Metastatic Mismatch Repair–Deficient Colorectal Cancer: Game-Changer for Small Group of Patients
PATIENTS WITH DNA mismatch repair–deficient (dMMR) metastatic colorectal cancer display a high level of microsatellite instability (MSI-H)1 and demonstrate poor chemosensitivity and shorter overall survival than patients with mismatch repair–proficient (pMMR) metastatic metastatic colorectal...
Expert Point of View: Nadia Harbeck, MD, PhD, and Sibylle Loibl, MD
NADIA HARBECK, MD, PhD, of the Breast Center at the University of Munich, Germany, said the findings of LORELEI are among a growing list of indications that “the future is bright for endocrine-based therapy.” Although the results were hypothesis-generating and not yet practice-changing, she...
‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC
OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...
‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC
OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...
Ontario Province–Wide Symptom Screening and Opioid Prescribing Rates in Older Patients With Cancer
In a study reported in the Journal of Oncology Practice, Barbera et al found that a province-wide effort to improve symptom screening and management has increased the frequency of screening but has not improved opioid prescription rates in elderly cancer patients with severe pain. A previous study...
Integrative Therapies in Palliative Care Project
Palliative care professionals are invited to participate in a unique project sponsored by the National Cancer Institute. Collinge and Associates, Inc, is seeking interdisciplinary professionals to help develop and evaluate a new online continuing education (CE/CME) course on the use of integrative...
MSLT-II Completion Lymph Node Dissection Trial: Practice Changing but Not Likely Practice Abandoning
PROBABLY THE MOST IMPORTANT advance in the treatment of newly diagnosed primary melanoma has been the incorporation of sentinel lymph node biopsy as part of initial surgical management. The routine use of sentinel lymph node biopsy, often termed “sentinel lymphadenectomy,” in appropriately...
Can We Have a Successful Vaccine Against Cancer?
EARLY IN our careers, few of us imagined that a vaccine could one day prevent cancer. Now, there is a vaccine that keeps the risks from human papillomavirus (HPV) at bay, and yet universal adoption of the HPV vaccine has been incomplete. As a result of misinformation about the vaccine—and its...
European Commission Approves Obinutuzumab for Previously Untreated Advanced Follicular Lymphoma
On September 22, Roche announced that the European Commission has approved obinutuzumab (Gazyvaro in Europe; available in the United States as Gazyva) in combination with chemotherapy, followed by obinutuzumab maintenance in patients achieving a response, as a new treatment for previously untreated ...
Lymphoma Physician-Scientist Oliver Press, MD, PhD, Dies at 65
Oliver Press, MD, PhD, a blood cancer physician-scientist who made foundational contributions to the development of targeted cancer therapies, died Friday of complications from glioma. He was 65 years old. Dr. Press was the David and Patricia Giuliani/Oliver Press Endowed Chair for Cancer Research ...
FDA Grants Priority Review for Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
On September 29, Roche announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application and granted Priority Review for pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, for adjuvant treatment of...
What Is the Most Important Factor Women Consider in Deciding on SERM Use to Reduce Their Risk of Breast Cancer?
Currently, two medications have been approved by the U.S. Food and Drug Administration to reduce the risk of breast cancer: tamoxifen and raloxifene. Both medications, selective estrogen receptor modulators (SERMs), have been shown to reduce the risk for breast cancer by up to 50% in prevention...
Biden Cancer Initiative: Accelerating Progress in Cancer Research
Earlier this year, at the Alexandria Center for Life Science, former Vice President Joe Biden and Jill Biden, PhD, launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care. The Biden Cancer Initiative will...
Increasing Racial and Ethnic Diversity in the Oncology Workforce
Although significant progress has been made in cancer incidence and mortality in the United States over the past 2 decades—the death rate fell 23% between 1991 and 20121—not everyone is benefiting equally. According to the American Cancer Society, blacks have the highest death rate and shortest...
ASTRO 2017: Uninsured Patients With Cancer Saw Increased Coverage for Care Following Medicaid Expansion
A new study found that Medicaid expansion enacted as part of the Patient Protection and Affordable Care Act (ACA) improved coverage for care for patients with cancer receiving radiation therapy and potentially decreased health-care disparities. Analysis of more than 197,000 patient records from one ...
ASTRO 2017: Accelerated Breast Radiation Therapy Following Mastectomy Can Shorten Treatment Time While Maintaining Tumor Control
Radiation therapy following mastectomy for intermediate-stage, high-risk breast cancer can be shortened from 5 to 3 weeks while maintaining tumor control rates in the breast and surrounding region that are equivalent to conventional treatment, according to research presented by Sun et al at the...
Bhishamjit S. Chera, MD, on Oropharyngeal Squamous Cell Carcinoma and HPV-16: Expert Perspective
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
ASTRO 2017: Aggressively Reduced Radiation Therapy May Benefit Some Patients With HPV-Related Throat Cancer
For certain patients with oropharyngeal cancer caused by the human papillomavirus (HPV), an aggressive reduction of radiation therapy after surgery may provide cancer control while simultaneously reducing post-treatment side effects, improving quality of life, and lowering treatment costs,...
Second Annual ASCO Advocacy Summit Convenes in Washington, DC
Nearly 100 oncology care providers from across the United States traveled to Capitol Hill on September 27 and 28 to participate in the second annual ASCO Advocacy Summit. Advocates met with Members of Congress and their staff to educate them on critical issues affecting patients with cancer ...
FDA Approves New CDK4/6 Inhibitor for Certain Advanced or Metastatic Breast Cancers
The U.S. Food and Drug Administration today approved abemaciclib (Verzenio) to treat adult patients who have hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. Abemaciclib is...
ASTRO 2017: Immune Response May Be Prognostic for Prostate Cancer Survival, Recurrence, and Response to Radiation Therapy
A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes. The analysis of more than 9,000 prostate tumors also found evidence that programmed cell death...
Cumulative Burden of Chronic Health Conditions in Childhood Cancer Survivors
In a report from the St Jude Lifetime Cohort Study published in The Lancet, Bhakta et al detailed the burden of lifetime chronic health conditions in survivors of childhood cancers. The report included retrospectively collected data on chronic health conditions in 5,522 patients treated for...
ASTRO 2017: Radiation-Immunotherapy Combination May Benefit Some Patients With Late-Stage Cancer
A new study involving patients with stage IV cancer has found that treatment with radiation therapy and immunotherapy can slow tumor growth by stimulating the body’s immune system to attack the cancer. In the phase II trial, patients with end-stage cancer that had metastasized to the lungs or ...
ASTRO 2017: Distress in Patients Receiving Radiation Associated With Missed Appointments, Hospitalization
Psychological distress has long been associated with negative health outcomes for patients with cancer, though specific reasons remain unclear. A new study has found that roughly half of all patients who reported having severe distress, which the National Comprehensive Cancer Network® (NCCN)...
ASTRO 2017: Biomarker Blood Test Predicts Survival Following Localized Lung Cancer Treatment
A new study demonstrates that a blood test to detect cancer may predict treatment outcomes for patients with localized non–small cell lung cancer (NSCLC) and afford physicians additional lead time to personalize treatment for recurrent disease. Patients in the study with detectable levels of...
Stemming the Growing Cancer Crisis in Rural Appalachia
A pair of recent studies show a troubling trend: Despite a 20% decrease in cancer mortality rates nationwide over the past 2 decades,1 Americans living in rural regions of the United States are more likely to die of cancer than persons living in metropolitan areas of the country. An analysis of...
Rhodiola
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present information on...
Emotional and Psychological Distress Associated With Prostate Cancer
A cancer diagnosis presents emotional and psychological challenges for patients and caregivers, and prostate cancer has some unique challenges, in part because management is not writ in stone. At several points along the trajectory of illness, men with prostate cancer face decisions that can be...
How a Child With Cancer Moved From Vulnerability to Resilience
At the time this article was published in the Journal of Clinical Oncology, Dr. Danaher was practicing at Monash -University, -Melbourne, Australia; Drs. Brand and Mack, at Dana-Farber Cancer Institute, Boston; Dr. Pickard, at the Imperial College -Healthcare NHS Trust, London; and Dr. Berry,...
Douglas R. Lowy, MD, and John T. Schiller, PhD, Receive 2017 Lasker Award
Two scientists at the National Cancer Institute (NCI) received the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize and was...
Kunle Odunsi, MD, PhD, FRCOG, FACOG, Named to NIH Immunology Grant Review Board
KUNLE ODUNSI, MD, PHD, FRCOG, FACOG, Deputy Director of Roswell Park Cancer Institute, has been appointed to the Transplantation, Tolerance, and Tumor (TTT) Immunology Study Section within the National Institutes of Health (NIH) Center for Scientific Review. The TTT section is the panel of peer...
U.S. Preventive Services Task Force Recommends Screening Most Adult Women for Cervical Cancer
THE U.S. PREVENTIVE SERVICES TASK FORCE has posted a draft recommendation statement and draft evidence review on screening for cervical cancer. The Task Force recommends that primary care clinicians screen for cervical cancer in women ages 21 to 29 every 3 years with cervical cytology, more...
Balancing Harms and Benefits of Cancer Screening: The Debate Continues
Over the past several decades, widespread cancer screening has saved lives from various cancer types. However, despite advances in early-detection technologies, many cancers still remain undetected until they become symptomatic, conferring poor prognoses and outcomes. Moreover, some methods of...
How Early Palliative Care May Benefit Patients With Incurable Cancer
Palliative care provided soon after a patient is diagnosed with incurable cancer not only helps improve the patient’s overall quality of life but also improves communication about the patient’s wishes for end-of-life care, according to a study by Jennifer S. Temel, MD, Clinical Director of Thoracic ...
Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed
The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for...
